Friday, February 18, 2011

Association of age-related macular degeneration with age-related hearing loss

Cambridge Journals Online - Abstract - Association of age-related macular degeneration with age-related hearing loss

Age-related hearing loss is more common in patients with age-related macular degeneration. Such patients should be questioned regarding hearing difficulty, and referred to an otolaryngologist if appropriate.



Tuesday, February 15, 2011

Quality of life of eye amputated patients - Rasmussen - 2011 - Acta Ophthalmologica - Wiley Online Library

Quality of life of eye amputated patients - Rasmussen - 2011 - Acta Ophthalmologica - Wiley Online Library

The impact of an eye amputation is considerable. The quality of life, perceived stress and self-rated health of many eye-amputated patients are drastically changed. Eye amputation has a marked negative influence on job separation because of illness or disability and on socioeconomic position.

Wednesday, February 09, 2011

Omega-3 supplement decreases dry eye symptoms in clinical trial - - ModernMedicine

Omega-3 supplement decreases dry eye symptoms in clinical trial - - ModernMedicine

Patients taking an omega–3 supplement had a self–reported reduction in dry eye symptoms and an increase in tear volume and tear flow compared with a group of controls who received placebos.

Multifocal Contact Lenses Help Slow Myopic Progression in Children

Effect of Dual-Focus Soft Contact Lens Wear on Axial Myopia Progression in Children

Myopia progression and eye elongation were reduced significantly in eyes wearing DF lenses. The data suggest that sustained myopic defocus, even when presented to the retina simultaneously with a clear image, can act to slow myopia progression without compromising visual function.

Progressive Addition Lenses versus Single Vision Lenses for Slowing Progression of Myopia in Children with High Accommodative Lag and Near Esophoria — Invest. Ophthalmol. Vis. Sci.

Progressive Addition Lenses versus Single Vision Lenses for Slowing Progression of Myopia in Children with High Accommodative Lag and Near Esophoria — Invest. Ophthalmol. Vis. Sci.

The PALs used in this study were found to have a statistically but not clinically significant effect on slowing myopia progression in children with high accommodative lag and near esophoria.

Wednesday, February 02, 2011

Patient attitudes and behavior regarding hygiene and replacement of soft contact lenses and storage cases

Patient attitudes and behavior regarding hygiene and replacement of soft contact lenses and storage cases

More than half of contact lens patients are not compliant with their 2-weekly or monthly schedule. Who cares about their eyes?

Physical Activity, Television Viewing Time, and Retinal Vasc... : Medicine & Science in Sports & Exercise

Physical Activity, Television Viewing Time, and Retinal Vasc... : Medicine & Science in Sports & Exercise

According to this study, TV watching longer than 2 hours per day causes increased vein diameter in males.

Dry eye treatment Phase III study - Ophthalmology Times Europe

Dry eye treatment Phase III study - Ophthalmology Times Europe

A treatment for dry eye syndrome is to undergo a phase III randomized, placebo-controlled, multicentre study this year following a final licensing agreement with Celtic Therapeutics.

Resolvyx Pharmacuticals' RX-10045 is a resolvin that will be administered as a topical eye drop. In a large Phase II placebo-controlled study it was found that the eye drop produced dose-dependent, improvement on the primary endpoints for both signs and symptoms of dry eye, and was shown to be safe and well-tolerated.

Resolvins have demonstrated high potency and efficacy in the treatment of dry eye and retinal disease as well as asthma, rheumatoid arthritis, inflammatory bowel disease and atherosclerosis.

Stephen Evans-Freke and Peter B Corr, co-founders and Managing General Partners of Celtic Therapeutics Holdings, said: "We look forward to a close and successful alliance with Resolvyx to optimize the medical potential and financial returns from this exciting class of novel anti-inflammatory molecules in the ophthalmology field. If approved, RX-10045 should provide superior efficacy to current therapeutic options in dry eye. We are eager to explore the activity of resolvins in additional ophthalmic indications as well."